MA54939A - Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 - Google Patents

Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2

Info

Publication number
MA54939A
MA54939A MA054939A MA54939A MA54939A MA 54939 A MA54939 A MA 54939A MA 054939 A MA054939 A MA 054939A MA 54939 A MA54939 A MA 54939A MA 54939 A MA54939 A MA 54939A
Authority
MA
Morocco
Prior art keywords
hydroxypyridoxazepines
nrf2 activators
nrf2
activators
hydroxypyridoxazepines used
Prior art date
Application number
MA054939A
Other languages
English (en)
Inventor
Mark Elban
Michal Pawel Glogowski
Michael Clinton Koetting
Brian Griffin Lawhorn
Jay M Matthews
Jaclyn Renee Patterson
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA54939A publication Critical patent/MA54939A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054939A 2019-02-15 2020-02-11 Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 MA54939A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806201P 2019-02-15 2019-02-15
US201962931877P 2019-11-07 2019-11-07

Publications (1)

Publication Number Publication Date
MA54939A true MA54939A (fr) 2021-12-22

Family

ID=69726636

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054939A MA54939A (fr) 2019-02-15 2020-02-11 Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2

Country Status (18)

Country Link
US (3) US11945826B2 (fr)
EP (1) EP3924356A1 (fr)
JP (1) JP7602469B2 (fr)
KR (1) KR102932313B1 (fr)
CN (2) CN113474349B (fr)
AU (1) AU2020222080C1 (fr)
BR (1) BR112021016042A2 (fr)
CA (1) CA3129955A1 (fr)
CL (1) CL2021002110A1 (fr)
CO (1) CO2021010930A2 (fr)
IL (2) IL285438B2 (fr)
MA (1) MA54939A (fr)
MX (1) MX2021009659A (fr)
MY (1) MY209603A (fr)
PH (1) PH12021551873A1 (fr)
SG (1) SG11202108257TA (fr)
TW (2) TWI843806B (fr)
WO (1) WO2020165776A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065501T2 (hu) 2018-08-20 2024-05-28 Janssen Pharmaceutica Nv A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok
JP7602469B2 (ja) * 2019-02-15 2024-12-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
MX2021014680A (es) 2019-05-31 2022-04-06 Ube Corp Derivado de benzotriazol.
PE20241779A1 (es) 2022-01-07 2024-09-03 Chugai Pharmaceutical Co Ltd Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del nrf2
JP7605446B2 (ja) 2022-04-28 2024-12-24 第一三共株式会社 ベンゾトリアゾール化合物
US20250296939A1 (en) * 2022-04-28 2025-09-25 Kyoto Pharmaceutical Industries, Ltd. Benzothiophene compound
WO2024047248A1 (fr) * 2022-09-02 2024-03-07 Institut National de la Santé et de la Recherche Médicale Utilisation d'activateurs de nrf2 pour le traitement de la maladie des petits vaisseaux cérébraux
WO2024262491A1 (fr) 2023-06-19 2024-12-26 中外製薬株式会社 Cristal d'un composé hétérocyclique contenant de l'azote ayant un effet d'activation de nrf2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094651A1 (fr) * 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthèse et activités biologiques de nouveaux composés tricycliques-bis-énones (tbe)
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CN104418834B (zh) * 2013-08-23 2017-09-15 重庆博腾制药科技股份有限公司 一种抗糖尿病药物中间体的合成方法
KR102301867B1 (ko) * 2013-12-18 2021-09-15 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
CN105272960A (zh) * 2014-07-18 2016-01-27 上海科胜药物研发有限公司 一种坎格列净中间体2-(2-甲基-5-溴苄基)-5-(4-氟苯)噻吩的制备方法
WO2016178148A1 (fr) * 2015-05-05 2016-11-10 Glenmark Pharmaceuticals Limited Procédé de préparation de dapagliflozine
SI3782996T1 (sl) 2015-06-15 2024-06-28 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulatorji
EP3766878B1 (fr) * 2015-06-15 2022-03-16 GlaxoSmithKline Intellectual Property Development Limited Régulateurs de nrf2
CA2988373A1 (fr) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Regulateurs de nrf2
US10201531B2 (en) * 2015-08-12 2019-02-12 Mochida Pharmaceutical Co., Ltd. Indazolyl-oxo-isothiazole compounds
US10364256B2 (en) * 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
WO2017130217A1 (fr) * 2016-01-27 2017-08-03 Msn Laboratories Private Limited Procédé de préparation de d-glucitol, 1,5- anhydro-1-c-[4-chloro-3-[[4-[[(3s)-tétrahydro-3-furanyl] oxy]phényl] méthyl]phényl]-, (1s) et ses formes cristallines
CN108779108A (zh) * 2016-12-06 2018-11-09 葛兰素史密斯克莱知识产权发展有限公司 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途
EP3551621A1 (fr) * 2016-12-12 2019-10-16 GlaxoSmithKline Intellectual Property Development Limited N-aryl pyrazoles en tant que régulateurs de nrf2
JP2020502136A (ja) * 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしてのビスアリールアミド
CA3044773A1 (fr) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Activateurs nrf2
JP7602469B2 (ja) * 2019-02-15 2024-12-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン

Also Published As

Publication number Publication date
CN118206566A (zh) 2024-06-18
CA3129955A1 (fr) 2020-08-20
JP7602469B2 (ja) 2024-12-18
US20220204526A1 (en) 2022-06-30
BR112021016042A2 (pt) 2021-10-05
MX2021009659A (es) 2021-09-08
TW202440593A (zh) 2024-10-16
US11945826B2 (en) 2024-04-02
PH12021551873A1 (en) 2022-05-23
TWI880702B (zh) 2025-04-11
IL285438A (en) 2021-09-30
AU2020222080C1 (en) 2022-09-29
US20240352034A1 (en) 2024-10-24
IL313950A (en) 2024-08-01
IL285438B2 (en) 2024-12-01
JP2022520442A (ja) 2022-03-30
US20250313573A1 (en) 2025-10-09
CN113474349B (zh) 2024-03-01
KR20210126676A (ko) 2021-10-20
MY209603A (en) 2025-07-24
TW202045514A (zh) 2020-12-16
IL285438B1 (en) 2024-08-01
AU2020222080A1 (en) 2021-09-02
AU2020222080B2 (en) 2022-05-19
CN113474349A (zh) 2021-10-01
WO2020165776A1 (fr) 2020-08-20
EP3924356A1 (fr) 2021-12-22
SG11202108257TA (en) 2021-08-30
CO2021010930A2 (es) 2021-09-09
KR102932313B1 (ko) 2026-02-26
TWI843806B (zh) 2024-06-01
CL2021002110A1 (es) 2022-02-11

Similar Documents

Publication Publication Date Title
MA54939A (fr) Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
EP3953331A4 (fr) Pyrazolesulfonamides en tant qu'agents antitumoraux
EP4013496A4 (fr) Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA50589A (fr) Compositions de pyrrolopyrrole en tant qu'activateurs de pyruvate kinase (pkr)
EP3861343A4 (fr) Nanoconstructions fluorescentes ultralégères en tant qu'amplificateurs universels
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
EP3883570A4 (fr) Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
EP3442973A4 (fr) Nouveaux composés utilisés en tant qu'inhibiteurs de l'autotaxine et compositions pharmaceutiques les comprenant
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3755311A4 (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
ITUA20161510A1 (it) Composizione per colorare la fibra cheratinica
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
EP3663049A4 (fr) Machine d'enfoncement
EP3886879A4 (fr) Plaquettes en tant qu'agents de livraison
MA50250A (fr) Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
MA49841A (fr) Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine